144 related articles for article (PubMed ID: 38309723)
21. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).
Bersanelli M; Buti S; Cortellini A; Bandini M; Banna GL; Pederzoli F; Farè E; Raggi D; Giannatempo P; De Giorgi U; Basso U; Losanno T; Santini D; Mucciarini C; Tucci M; Tambaro R; Farnesi A; Caffo O; Veccia A; Naglieri E; Briganti A; Procopio G; Pignata S; Necchi A
Clin Med Insights Oncol; 2021; 15():11795549211021667. PubMed ID: 34290538
[TBL] [Abstract][Full Text] [Related]
22. Systemic treatments for metastatic urothelial carcinoma.
Lalani AA; Sonpavde GP
Expert Opin Pharmacother; 2019 Feb; 20(2):201-208. PubMed ID: 30412003
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
[TBL] [Abstract][Full Text] [Related]
24. Treatment Patterns and Real-World Outcomes for Locally Advanced or Metastatic Urothelial Cancer in the Era of Immunotherapy.
Hassler MR; Moedlagl V; Hindinger H; Krauter J; Klager S; Resch I; Huebner N; Yurdakul O; Ofner H; Korn SM; D'Andrea D; Gust K; Shariat SF
Eur Urol Focus; 2023 Dec; ():. PubMed ID: 38161107
[TBL] [Abstract][Full Text] [Related]
25. Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis.
Yanagisawa T; Kawada T; Quhal F; Bekku K; Laukhtina E; Rajwa P; von Deimling M; Majdoub M; Chlosta M; Pradere B; Mori K; Kimura T; Schmidinger M; Karakiewicz PI; Shariat SF
World J Urol; 2023 Jul; 41(7):1763-1774. PubMed ID: 37209143
[TBL] [Abstract][Full Text] [Related]
26. Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward.
Bilé-Silva A; Lopez-Beltran A; Blanca A; Lopez-Rios F; Gómez-Gómez E; Cimadamore A; Montironi R; Vau N; Cheng L
Expert Opin Biol Ther; 2023 May; 23(5):407-418. PubMed ID: 37036223
[TBL] [Abstract][Full Text] [Related]
27. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
28. Dataset for: Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune-related adverse events.
Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
Data Brief; 2024 Apr; 53():110062. PubMed ID: 38317734
[TBL] [Abstract][Full Text] [Related]
29. High-throughput and multi-phases identification of autoantibodies in diagnosing early-stage breast cancer and subtypes.
Luo R; Zheng C; Song W; Tan Q; Shi Y; Han X
Cancer Sci; 2022 Feb; 113(2):770-783. PubMed ID: 34843149
[TBL] [Abstract][Full Text] [Related]
30. Omega-3 fatty acid intake suppresses induction of diverse autoantibody repertoire by crystalline silica in lupus-prone mice.
Rajasinghe LD; Li QZ; Zhu C; Yan M; Chauhan PS; Wierenga KA; Bates MA; Harkema JR; Benninghoff AD; Pestka JJ
Autoimmunity; 2020 Nov; 53(7):415-433. PubMed ID: 32903098
[TBL] [Abstract][Full Text] [Related]
31. Cardiomyopathy - An approach to the autoimmune background.
Becker NP; Müller J; Göttel P; Wallukat G; Schimke I
Autoimmun Rev; 2017 Mar; 16(3):269-286. PubMed ID: 28163240
[TBL] [Abstract][Full Text] [Related]
32. Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.
Mullane SA; Werner L; Guancial EA; Lis RT; Stack EC; Loda M; Kantoff PW; Choueiri TK; Rosenberg J; Bellmunt J
Clin Genitourin Cancer; 2016 Aug; 14(4):352-9. PubMed ID: 26778300
[TBL] [Abstract][Full Text] [Related]
33. Development of a protein microarray for profiling circulating autoantibodies in human diseases.
Ren J; Wang H; Wei C; Yang X; Yu X
Proteomics Clin Appl; 2022 Nov; 16(6):e2100132. PubMed ID: 36006834
[TBL] [Abstract][Full Text] [Related]
34. Single-centre Experience of Patients with Metastatic Urothelial Cancer Treated with Chemotherapy Following Immune Checkpoint Inhibition.
Lam JM; Liu WK; Powles T; Tang YZ; Szabados B
Eur Urol Oncol; 2021 Aug; 4(4):659-662. PubMed ID: 31151926
[TBL] [Abstract][Full Text] [Related]
35. EpCAM-autoantibody levels in the course of disease of ovarian cancer patients.
Heubner M; Errico D; Kasimir-Bauer S; Herlyn D; Kimmig R; Wimberger P
Med Oncol; 2011 Jun; 28(2):626-30. PubMed ID: 20383668
[TBL] [Abstract][Full Text] [Related]
36. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients.
Troyanov Y; Targoff IN; Tremblay JL; Goulet JR; Raymond Y; Senécal JL
Medicine (Baltimore); 2005 Jul; 84(4):231-249. PubMed ID: 16010208
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.
Meynard L; Dinart D; Delaunay B; Fléchon A; Saldana C; Lefort F; Gravis G; Thiery-Vuillemin A; Cancel M; Coquan E; Ladoire S; Maillet D; Rolland F; Boughalem E; Martin S; Laramas M; Crouzet L; Abbar B; Falkowski S; Pouessel D; Roubaud G
Eur J Cancer; 2022 Nov; 175():43-53. PubMed ID: 36088671
[TBL] [Abstract][Full Text] [Related]
38. Are sputum autoantibodies more clinically relevant in idiopathic pulmonary fibrosis than serum autoantibodies?
Deng K; Luo Q; Liang Z; Long F; Han Q; Wang F; Huang S; Liao L; Lin T; Chen R
J Res Med Sci; 2022; 27():3. PubMed ID: 35342449
[TBL] [Abstract][Full Text] [Related]
39. High-Throughput Antigen Microarray Identifies Longitudinal Prognostic Autoantibody for Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer.
Dai L; Tan Q; Li L; Lou N; Zheng C; Yang J; Huang L; Wang S; Luo R; Fan G; Xie T; Yao J; Zhang Z; Tang L; Shi Y; Han X
Mol Cell Proteomics; 2024 May; 23(5):100749. PubMed ID: 38513890
[TBL] [Abstract][Full Text] [Related]
40. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
Talukder R; Makrakis D; Lin GI; Diamantopoulos LN; Dawsey S; Gupta S; Carril-Ajuria L; Castellano D; de Kouchkovsky I; Jindal T; Koshkin VS; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Tripathi N; Agarwal N; Vather-Wu N; Zakharia Y; Morales-Barrera R; Devitt ME; Cortellini A; Fulgenzi CAM; Pinato DJ; Nelson A; Hoimes CJ; Gupta K; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Murgic J; Fröbe A; Rodriguez-Vida A; Drakaki A; Liu S; Lu E; Kumar V; Lorenzo GD; Joshi M; Isaacsson-Velho P; Buznego LA; Duran I; Moses M; Barata P; Sonpavde G; Wright JL; Yu EY; Montgomery RB; Hsieh AC; Grivas P; Khaki AR
Clin Genitourin Cancer; 2022 Dec; 20(6):558-567. PubMed ID: 36155169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
